Drug Profile
Goflikicept - TRPHARM
Alternative Names: RPH-104Latest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator TRPHARM
- Developer R-Pharm; TRPHARM
- Class Analgesics; Anti-inflammatories; Recombinant fusion proteins
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Pericarditis
- Phase II/III SARS-CoV-2 acute respiratory disease
- Phase II Familial Mediterranean fever; Myocardial infarction; Pain
Most Recent Events
- 11 Nov 2023 Efficacy and adverse events data from a phase IIa trial in Myocardial infarction presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)
- 10 Oct 2022 R-Pharm completes a phase II trial in Myocardial infarction in USA and Russia (SC) (NCT04463251)
- 27 Jun 2022 R-Pharm plans a phase III trial in Adult-onset-Still's-disease in Russia in August 2022 (NCT05432960)